1. Home
  2. WNW vs TPST Comparison

WNW vs TPST Comparison

Compare WNW & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

HOLD

Current Price

$3.59

Market Cap

25.8M

ML Signal

HOLD

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNW
TPST
Founded
2015
2011
Country
China
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
30.9M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
WNW
TPST
Price
$3.59
$1.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
47.8M
134.9K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$1.50
52 Week High
$13.52
$12.22

Technical Indicators

Market Signals
Indicator
WNW
TPST
Relative Strength Index (RSI) 74.95 31.12
Support Level $1.40 $1.50
Resistance Level $13.52 $2.49
Average True Range (ATR) 0.20 0.16
MACD 0.43 -0.01
Stochastic Oscillator 66.75 11.88

Price Performance

Historical Comparison
WNW
TPST

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: